skip to main content

Press Release

Nouveau Biosciences Appoints Andrew L. Pecora, M.D., as Chairman of its Scientific Advisory Board

Nouveau Biosciences Appoints Andrew L. Pecora, M.D., as Chairman of its Scientific Advisory Board

Renowned oncologist, healthcare innovator and biotechnology entrepreneur brings decades of experience in cancer research, cellular medicine and precision oncology to Nouveau [NEW YORK, September 22, 2026] — Nouveau Biosciences, a biotechnology company developing precision-targeted nanomedicines for cancer, today announced the appointment of Andrew L. Pecora, M.D., FACP, CPE, as Chairman of its Scientific Advisory Board. […]

Nouveau Biosciences and DarwinHealth (TM) Enter Collaboration to Advance Precision Oncology Drug Discovery

Nouveau Biosciences and DarwinHealth (TM) Enter Collaboration to Advance Precision Oncology Drug Discovery

Collaboration will combine DarwinHealth’s systems-biology, AI, and computational oncology platform with Nouveau Biosciences’ precision nanotherapeutic technology to develop therapies tailored to cancer biology [NEW YORK, September 15, 2025] — Nouveau Biosciences, a biotechnology company developing precision nanomedicines for cancer, today announced that it has entered into a collaboration with DarwinHealth™ to identify and develop novel therapeutic […]

Nouveau Biosciences Appoints Robert Langer, Sc.D., to Scientific Advisory Board

Nouveau Biosciences Appoints Robert Langer, Sc.D., to Scientific Advisory Board

World-renowned MIT scientist and pioneering biomedical engineer brings decades of leadership in drug delivery, biomaterials and biotechnology to Nouveau’s precision oncology platform [NEW YORK, September 8, 2026] — Nouveau Biosciences, a biotechnology company developing precision-targeted nanomedicines for cancer, today announced the appointment of Robert Langer, Sc.D., David H. Koch (1962) Institute Professor at the Massachusetts […]

Nouveau Biosciences Recruits Deepthi Damera, Ph.D. to Lead Nanotherapeutics Drug Development

Nouveau Biosciences Recruits Deepthi Damera, Ph.D. to Lead Nanotherapeutics Drug Development

[New York, NY – June 5, 2026] – Nouveau Biosciences is proud to announce the recruitment of Deepthi Damera, Ph.D. to lead its nanochemistry programs at Nouveau Research Technologies, the company laboratory.  Dr. Damera is a highly accomplished biophysicist who has spent the past decade intimately involved in all aspects of nanotechnology, from fabrication to biophysical characterization. […]

Nouveau Biosciences and University of Virginia (UVA) Announce Second Licensing Agreement to Expand the Company’s Unique Pipeline of Innovative Nanomedicines

Nouveau Biosciences and University of Virginia (UVA) Announce Second Licensing Agreement to Expand the Company’s Unique Pipeline of Innovative Nanomedicines

[New York, NY – February, 10, 2026] – Nouveau Biosciences, a biotechnology company pioneering nanomedicines and targeted drug delivery to improve cancer therapeutics, today announced that it has executed a second Licensing Agreement with the University of Virginia (UVA) to expand the company’s pipeline. The Licensing Agreement ratifies Nouveau’s rights to six additional novel nanomedicine […]

Nouveau Biosciences and Ardena Enter Agreement to Make Clinical Grade Kromastat, an Innovative Nanomedicine for Early Phase Studies

Nouveau Biosciences and Ardena Enter Agreement to Make Clinical Grade Kromastat, an Innovative Nanomedicine for Early Phase Studies

Nouveau Biosciences and Ardena Enter Agreement to Make Clinical Grade Kromastat, an Innovative Nanomedicine for Early Phase Studies [New York, NY – January 5, 2026] Nouveau Biosciences, a biotechnology company pioneering new approaches to discover novel targeted nanomedicines to improve cancer therapeutics, today announced that it has entered into an agreement with Ardena to manufacture […]

Nouveau Biosciences Appoints Joseph Turgeon as Chief Operating Officer

Nouveau Biosciences Appoints Joseph Turgeon as Chief Operating Officer

[New York, NY – September 16, 2025] – Nouveau Biosciences, a biotechnology company pioneering nanomedicine and targeted oncology therapeutics, today announced the appointment of Joseph Turgeon as Chief Operating Officer. Mr. Turgeon brings more than 38 years of experience in the pharmaceutical and biotechnology industries, with a career distinguished by leadership in oncology drug development, […]

Nouveau Biosciences Appoints Keith M. McGahan as Chief Legal Officer

Nouveau Biosciences Appoints Keith M. McGahan as Chief Legal Officer

[New York, NY – September 16, 2025] – Nouveau Biosciences, a biotechnology company pioneering next-generation nanomedicine and targeted oncology therapeutics, today announced the appointment of Keith M. McGahan as Chief Legal Officer. Mr. McGahan brings more than two decades of executive leadership experience across the healthcare, pharmaceutical, and life sciences sectors, with a distinguished track […]